Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges

Autor: Marta Marquié, Miren Ettcheto, Maria Luisa García, Mercè Boada, Agustín Ruiz, Giovanni Tosi, Jason T. Duskey, Amanda Cano, Patric Turowski, Elena Sánchez-López, Eliana B. Souto, Antonio Camins
Přispěvatelé: Universidade do Minho
Rok vydání: 2021
Předmět:
Aging
Pharmaceutical Science
Medicine (miscellaneous)
Disease
Review
Diagnostic tools
Applied Microbiology and Biotechnology
0302 clinical medicine
Drug Delivery Systems
Nanotechnology
Disease management (health)
0303 health sciences
Nanopartícules
Malalties neurodegeneratives
Brain
Neurodegenerative Diseases
Alzheimer's disease
3. Good health
Nanomedicine
Late diagnosis
Nanomedicina
Molecular Medicine
Alzheimer’s disease
Biotechnology
medicine.medical_specialty
Biomarkers
Lipid nanoparticles
Metal nanoparticles
Polymeric nanoparticles
Biomedical Engineering
Bioengineering
03 medical and health sciences
Therapeutic approach
Alzheimer Disease
Medical technology
medicine
Dementia
Diagnostic biomarker
Animals
Humans
R855-855.5
Intensive care medicine
030304 developmental biology
Science & Technology
Amyloid beta-Peptides
business.industry
Biomarkers
Polymeric nanoparticles
medicine.disease
Oxidative Stress
Malaltia d'Alzheimer
Alzheimers disease
Life expectancy
Nanoparticles
business
TP248.13-248.65
030217 neurology & neurosurgery
Zdroj: Journal of Nanobiotechnology
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Dipòsit Digital de la UB
Universidad de Barcelona
Journal of Nanobiotechnology, Vol 19, Iss 1, Pp 1-30 (2021)
ISSN: 1477-3155
Popis: Increasing life expectancy has led to an aging population, which has consequently increased the prevalence of dementia. Alzheimer's disease (AD), the most common form of dementia worldwide, is estimated to make up 50--80% of all cases. AD cases are expected to reach 131 million by 2050, and this increasing prevalence will critically burden economies and health systems in the next decades. There is currently no treatment that can stop or reverse disease progression. In addition, the late diagnosis of AD constitutes a major obstacle to effective disease management. Therefore, improved diagnostic tools and new treatments for AD are urgently needed. In this review, we investigate and describe both well-established and recently discovered AD biomarkers that could potentially be used to detect AD at early stages and allow the monitoring of disease progression. Proteins such as NfL, MMPs, p-tau217, YKL-40, SNAP-25, VCAM-1, and Ng BACE are some of the most promising biomarkers because of their successful use as diagnostic tools. In addition, we explore the most recent molecular strategies for an AD therapeutic approach and nanomedicine-based technologies, used to both target drugs to the brain and serve as devices for tracking disease progression diagnostic biomarkers. State-of-the-art nanoparticles, such as polymeric, lipid, and metal-based, are being widely investigated for their potential to improve the effectiveness of both conventional drugs and novel compounds for treating AD. The most recent studies on these nanodevices are deeply explained and discussed in this review.
Authors acknowledge the support of the Instituto de Salud Carlos III (ISCIII) Accion Estrategica en Salud, integrated in the Spanish National R+D+I Plan and financed by ISCIII Subdireccion General de Evaluacion and the Fondo Europeo de Desarrollo Regional (FEDER "Una manera de hacer Europa") grant PI17/01474 awarded to Merce Boada and grant PI19/00335 awarded to Marta Marquie; Spanish Ministry of Economy and Competitiveness (SAF201784283-R); Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED, CB06/05/0024); Portuguese Science and Technology Foundation (FCT) for the strategic fund (UIDB/04469/2020) and European Regional Development Funds.
info:eu-repo/semantics/publishedVersion
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje